Do analysts prefer BCTX or XBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer BCTX or XBIO?

In the previous week, Briacell Therap and Briacell Therap both had 3 articles in the media. Briacell Therap's average media sentiment score of 0.82 beat Xenetic Biosciences' score of 0.53 indicating that Briacell Therap is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenetic Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate KYNB or XBIO?

Kyntra Bio presently has a consensus target price of $32.50, indicating a potential upside of 305.24%. Given Kyntra Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Kyntra Bio is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend XBIO or ESLA?

Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 1,034.59%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Estrella Immunopharma is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer XBIO or ESLA?

In the previous week, Xenetic Biosciences and Xenetic Biosciences both had 3 articles in the media. Estrella Immunopharma's average media sentiment score of 0.63 beat Xenetic Biosciences' score of 0.53 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenetic Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ATNM or XBIO?

Actinium Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 395.05%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate QNCX or XBIO?

Quince Therapeutics currently has a consensus price target of $260.00, suggesting a potential upside of 670.37%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 2 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.42 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to QNCX or XBIO?

In the previous week, Quince Therapeutics and Quince Therapeutics both had 3 articles in the media. Quince Therapeutics' average media sentiment score of 0.80 beat Xenetic Biosciences' score of 0.53 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenetic Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xenetic Biosciences (XBIO) Competitors

$3.98 +0.01 (+0.25%)

As of 08/28/2026 04:00 PM Eastern

Compare

XBIO vs. BCTX, KYNB, ESLA, ATNM, and QNCX

Should you buy Xenetic Biosciences stock or one of its competitors? Xenetic Biosciences's main competitors and comparable companies include Briacell Therap (BCTX), Kyntra Bio (KYNB), Estrella Immunopharma (ESLA), Actinium Pharmaceuticals (ATNM), and Quince Therapeutics (QNCX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Xenetic Biosciences compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Briacell Therap has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Xenetic Biosciences' return on equity of -40.62% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Briacell Therap has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Xenetic Biosciences has higher revenue and earnings than Briacell Therap. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Xenetic Biosciences	$3.26M	2.80	-$2.68M	-$1.16	N/A

In the previous week, Briacell Therap and Briacell Therap both had 3 articles in the media. Briacell Therap's average media sentiment score of 0.82 beat Xenetic Biosciences' score of 0.53 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenetic Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xenetic Biosciences beats Briacell Therap on 7 of the 11 factors compared between the two stocks.

How does Xenetic Biosciences compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Kyntra Bio has higher revenue and earnings than Xenetic Biosciences. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	5.04	$183.45M	$45.30	0.18
Xenetic Biosciences	$3.26M	2.80	-$2.68M	-$1.16	N/A

Kyntra Bio has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market.

Kyntra Bio presently has a consensus target price of $32.50, indicating a potential upside of 305.24%. Given Kyntra Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Kyntra Bio is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Xenetic Biosciences had 2 more articles in the media than Kyntra Bio. MarketBeat recorded 3 mentions for Xenetic Biosciences and 1 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 1.89 beat Xenetic Biosciences' score of 0.53 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Kyntra Bio	Very Positive
Xenetic Biosciences	Positive

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Kyntra Bio has a net margin of 2,199.13% compared to Xenetic Biosciences' net margin of -75.90%. Kyntra Bio's return on equity of 0.00% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Summary

Kyntra Bio beats Xenetic Biosciences on 13 of the 17 factors compared between the two stocks.

How does Xenetic Biosciences compare to Estrella Immunopharma?

Xenetic Biosciences (NASDAQ:XBIO) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

Estrella Immunopharma has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Estrella Immunopharma's return on equity of 0.00% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-75.90%	-40.62%	-34.97%
Estrella Immunopharma	N/A	N/A	-328.72%

Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 1,034.59%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Estrella Immunopharma is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Xenetic Biosciences and Xenetic Biosciences both had 3 articles in the media. Estrella Immunopharma's average media sentiment score of 0.63 beat Xenetic Biosciences' score of 0.53 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenetic Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Xenetic Biosciences has a beta of 2.1, meaning that its stock price is 110% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Xenetic Biosciences has higher revenue and earnings than Estrella Immunopharma. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$3.26M	2.80	-$2.68M	-$1.16	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

Summary

Estrella Immunopharma beats Xenetic Biosciences on 8 of the 14 factors compared between the two stocks.

How does Xenetic Biosciences compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Xenetic Biosciences had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 3 mentions for Xenetic Biosciences and 0 mentions for Actinium Pharmaceuticals. Xenetic Biosciences' average media sentiment score of 0.53 beat Actinium Pharmaceuticals' score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Xenetic Biosciences	Positive

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Actinium Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 395.05%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Xenetic Biosciences has lower revenue, but higher earnings than Actinium Pharmaceuticals. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	0.90	-$48.82M	$0.36	2.81
Xenetic Biosciences	$3.26M	2.80	-$2.68M	-$1.16	N/A

Actinium Pharmaceuticals has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market.

Actinium Pharmaceuticals has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Xenetic Biosciences' return on equity of -40.62% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Summary

Actinium Pharmaceuticals and Xenetic Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Xenetic Biosciences compare to Quince Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

In the previous week, Quince Therapeutics and Quince Therapeutics both had 3 articles in the media. Quince Therapeutics' average media sentiment score of 0.80 beat Xenetic Biosciences' score of 0.53 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenetic Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xenetic Biosciences has higher revenue and earnings than Quince Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
Xenetic Biosciences	$3.26M	2.80	-$2.68M	-$1.16	N/A

Quince Therapeutics currently has a consensus price target of $260.00, suggesting a potential upside of 670.37%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.42
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Quince Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market.

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Quince Therapeutics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Quince Therapeutics' return on equity of 0.00% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Summary

Quince Therapeutics beats Xenetic Biosciences on 9 of the 15 factors compared between the two stocks.

Get Xenetic Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XBIO vs. The Competition

Export

Metric	Xenetic Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.12M	$3.94B	$7.21B	$12.91B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-3.43	6.73	212.12	21.89
Price / Sales	2.80	1,342.43	624.48	91.89
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	1.50	16.53	12.98	6.14
Net Income	-$2.68M	-$22.80M	$3.48B	$348.86M
7 Day Performance	10.86%	-0.30%	0.13%	-0.80%
1 Month Performance	65.42%	11.84%	8.37%	5.56%
1 Year Performance	38.48%	55.46%	24.55%	15.57%

Xenetic Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XBIO Xenetic Biosciences	0.5053 of 5 stars	$3.98 +0.3%	N/A	+37.5%	$9.12M	$3.26M	N/A	4	News Coverage Short Interest Increase
BCTX Briacell Therap	0.9679 of 5 stars	$4.03 +6.9%	N/A	-48.9%	$32.80M	N/A	N/A	8
KYNB Kyntra Bio	3.2066 of 5 stars	$8.10 flat	$32.50 +301.2%	N/A	$32.80M	$6.44M	0.18	570	Positive News
ESLA Estrella Immunopharma	1.7672 of 5 stars	$0.73 -0.3%	$8.00 +995.9%	-26.6%	$31.86M	N/A	N/A	N/A	Upcoming Earnings Analyst Upgrade Gap Up
ATNM Actinium Pharmaceuticals	1.8662 of 5 stars	$1.01 -6.5%	$5.00 +395.0%	-42.0%	$31.76M	$35.09M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XBIO) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenetic Biosciences (XBIO) Competitors

XBIO vs. BCTX, KYNB, ESLA, ATNM, and QNCX

How does Xenetic Biosciences compare to Briacell Therap?

Summary

How does Xenetic Biosciences compare to Kyntra Bio?

Summary

How does Xenetic Biosciences compare to Estrella Immunopharma?

Summary

How does Xenetic Biosciences compare to Actinium Pharmaceuticals?

Summary

How does Xenetic Biosciences compare to Quince Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIO vs. The Competition

Xenetic Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenetic Biosciences (XBIO) Competitors

XBIO vs. BCTX, KYNB, ESLA, ATNM, and QNCX

How does Xenetic Biosciences compare to Briacell Therap?

Do analysts prefer BCTX or XBIO?

Is BCTX or XBIO more profitable?

Which has more risk and volatility, BCTX or XBIO?

Do institutionals & insiders hold more shares of BCTX or XBIO?

Which has higher valuation & earnings, BCTX or XBIO?

Does the media prefer BCTX or XBIO?

Summary

How does Xenetic Biosciences compare to Kyntra Bio?

Which has preferable earnings and valuation, KYNB or XBIO?

Which has more volatility & risk, KYNB or XBIO?

Do analysts rate KYNB or XBIO?

Does the media refer more to KYNB or XBIO?

Do institutionals & insiders believe in KYNB or XBIO?

Is KYNB or XBIO more profitable?

Summary

How does Xenetic Biosciences compare to Estrella Immunopharma?

Is XBIO or ESLA more profitable?

Do analysts recommend XBIO or ESLA?

Does the media prefer XBIO or ESLA?

Do institutionals & insiders hold more shares of XBIO or ESLA?

Which has more volatility and risk, XBIO or ESLA?

Which has higher valuation & earnings, XBIO or ESLA?

Summary

How does Xenetic Biosciences compare to Actinium Pharmaceuticals?

Does the media refer more to ATNM or XBIO?

Do institutionals and insiders have more ownership in ATNM or XBIO?

Do analysts prefer ATNM or XBIO?

Which has higher valuation & earnings, ATNM or XBIO?

Which has more risk & volatility, ATNM or XBIO?

Is ATNM or XBIO more profitable?

Summary

How does Xenetic Biosciences compare to Quince Therapeutics?

Does the media refer more to QNCX or XBIO?

Which has higher earnings & valuation, QNCX or XBIO?

Do analysts rate QNCX or XBIO?

Which has more risk & volatility, QNCX or XBIO?

Do insiders and institutionals have more ownership in QNCX or XBIO?

Is QNCX or XBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIO vs. The Competition

Xenetic Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools